Abstract

TAB182 (also named TNKS1BP1), a binding protein of tankyrase 1, has been found to participate in DNA repair. Our previous study has revealed the involvement of TAB182 in the radioresistance of esophageal squamous cell carcinoma (ESCC) cells. However, whether TAB182 contributes to the ESCC tumorigenesis and progression remains unclear. In this study, we found that highly expressed TAB182 is closely associated with a poor prognosis of patients with ESCC. TAB182 silencing reduced ESCC cell proliferation and invasion in vitro, tumorigenicity and metastasis in vivo. RNA-seq and IP-MS analysis revealed that TAB182 could affect the β-catenin signaling pathway via interacting with β-catenin. Furthermore, TAB182 prevented β-catenin to be phosphorylated by GSK3β and recruited four and a half of LIM-only protein 2 (FHL2), which thereby promoted β-catenin nucleus translocation to result in activation of the downstream targets transcription in ESCC cells. Our findings demonstrate that TAB182 enhances tumorigenesis of esophageal cancer by promoting the activation of the β-catenin signaling pathway, which provides new insights into the molecular mechanisms by which TAB182 accelerates progression of ESCC.

Details

Title
TAB182 aggravates progression of esophageal squamous cell carcinoma by enhancing β-catenin nuclear translocation through FHL2 dependent manner
Author
Gao, Aidi 1 ; Su, Zhenzi 2 ; Shang, Zengfu 3   VIAFID ORCID Logo  ; He, Chao 1 ; Miao, Dongliu 1 ; Li, Xiaoqing 1 ; Zou, Shitao 1 ; Ding, Weiqun 4 ; Zhou, Yue 5   VIAFID ORCID Logo  ; Sun, Ming 6   VIAFID ORCID Logo  ; Zhou, Jundong 1   VIAFID ORCID Logo 

 The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Cancer Center Core Laboratory, Suzhou, P.R. China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984) 
 The Affiliated Suqian Hospital of Xuzhou Medical University and Nanjing Drum Tower Hospital Group Suqian Hospital, Suqian, P.R. China (GRID:grid.428392.6) (ISNI:0000 0004 1800 1685) 
 Medical College of Soochow University, School of Radiation Medicine and Protection, Suzhou, China (GRID:grid.263761.7) (ISNI:0000 0001 0198 0694) 
 University of Oklahoma Health Science Center, Department of Pathology, Oklahoma City, USA (GRID:grid.266902.9) (ISNI:0000 0001 2179 3618) 
 First Affiliated Hospital of Nanjing Medical University, Department of Thoracic Surgery, Nanjing, China (GRID:grid.412676.0) (ISNI:0000 0004 1799 0784) 
 The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Suzhou Cancer Center Core Laboratory, Suzhou, China (GRID:grid.440227.7) (ISNI:0000 0004 1758 3572) 
Pages
900
Publication year
2022
Publication date
Oct 2022
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2728809526
Copyright
© The Author(s) 2022. corrected publication 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.